BlueWillow Biologics

Blue Willow Biologics

Biotechnology, 2311 Green Rd, Ann Arbor, Michigan, 48105, United States, 11-50 Employees

bluewillow.com

  • facebook
  • twitter
  • LinkedIn

phone no Phone Number: 17*********

Who is BLUEWILLOW BIOLOGICS

BlueWillow Biologics® is developing and enabling a new generation of safe and effective nasal vaccines to protect global populations from respiratory infections, sexually transmitted dise...

Read More

map

industries-icon Industry: Biotechnology

SIC SIC Code: 2836 | NAICS Code: 325414 | Show More

checked-icon Does something look wrong? Fix it. | View contact records from BLUEWILLOW BIOLOGICS

BlueWillow Biologics Org Chart and Mapping

Chad Costley

Chief Executive Officer

Employees

Chris Brigolin

Senior Research Associate

Shyamala Ganesan

Senior Director Vaccine R&D

Jessie Pannu

Manager of Tech Transfer & Manufacturing/ Qa&Qc Lead/ Scientist

Stephen Gracon

VP Regulatory and Quality

Rone Eisma

Senior Research Associate

Laura Scallion

Director of Human Resources & Controller

Chris Euritt

Human Resources Consultant

signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

crown-icon Free credits every month

Frequently Asked Questions Regarding BlueWillow Biologics

Answer: BlueWillow Biologics's headquarters are located at 2311 Green Rd, Ann Arbor, Michigan, 48105, United States

Answer: BlueWillow Biologics's phone number is 17*********

Answer: BlueWillow Biologics's official website is https://bluewillow.com

Answer: BlueWillow Biologics's revenue is $25 Million to $50 Million

Answer: BlueWillow Biologics's SIC: 2836

Answer: BlueWillow Biologics's NAICS: 325414

Answer: BlueWillow Biologics has 11-50 employees

Answer: BlueWillow Biologics is in Biotechnology

Answer: BlueWillow Biologics contact info: Phone number: 17********* Website: https://bluewillow.com

Answer: BlueWillow Biologics® is developing and enabling a new generation of safe and effective nasal vaccines to protect global populations from respiratory infections, sexually transmitted diseases, and food allergies. Our novel intranasal NanoVax® adjuvant platform activates mucosal immunity, the body’s first line of defense, while also inducing systemic immunity. We are a clinical-stage company advancing a pipeline of proprietary programs including Peanut Allergy, HSV-2, Covid-19, Anthrax, Pandemic Flu and RSV.

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access